

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau

(43) International Publication Date  
27 September 2001 (27.09.2001)

PCT

(10) International Publication Number  
**WO 01/70770 A2**(51) International Patent Classification<sup>7</sup>: C07K 7/08,  
A61K 47/48[TR/US]; 50 East 98th Street, Apt. 2F, New York, NY  
10029 (US). KOHANSKI, Ron [US/US]; 8-24 Fairhaven  
Place, Fair Lawn, NJ 07410 (US).

(21) International Application Number: PCT/US01/08886

(22) International Filing Date: 21 March 2001 (21.03.2001)

(74) Agents: KAGAN, Sarah, A. et al.; Banner & Witcoff,  
Ltd., 1001 G Street, N.W., Eleventh Floor, Washington, DC  
20001-4597 (US).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/190,799 21 March 2000 (21.03.2000) US(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,  
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,  
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,  
TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.(63) Related by continuation (CON) or continuation-in-part  
(CIP) to earlier application:US 60/190,799 (CON)  
Filed on 21 March 2000 (21.03.2000)(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW). Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM). European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR). OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).(71) Applicant (*for all designated States except US*): THE  
JOHNS HOPKINS UNIVERSITY [US/US]; 111 Market  
Place, Suite 906, Baltimore, MD 21202 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): COURTNEY, Aliya  
[US/US]; JHMI, 725 N. Wolfe Street, 316 Hunterian Bldg.,  
Baltimore, MD 21205 (US). COLE, Philip, A. [US/US]; 5  
Wendover Road, Baltimore, MD 21218 (US). PARANG,  
Keykavous [CA/US]; Apt. 7019, 3333 North Charles  
Street, Baltimore, MD 21218 (US). ABLOOGU, Ararat

Published:

— without international search report and to be republished  
upon receipt of that reportFor two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

WO 01/70770 A2

(54) Title: BISUBSTRATE INHIBITORS OF KINASES

(57) Abstract: Protein kinase inhibitors have applications as anti-cancer therapeutic agents and biological tools in cell signalling. Potent and selective bisubstrate inhibitors for the insulin receptor tyrosine kinase are based on a phosphoryl transfer mechanism involving a dissociative transition state. One such inhibitor is synthesized by linking ATP<sub>γ</sub>S to a peptide substrate analog via a two-carbon spacer. The compound is a high-affinity competitive inhibitor against both nucleotide and peptide substrate and shows a slow off-rate. A crystal structure of this inhibitor bound to the tyrosine kinase domain of the insulin receptor confirms the key design features inspired by a dissociative transition state, and reveal that the linker takes part in the octahedral coordination of an active site Mg<sup>2+</sup> ion.

[01]

## BISUBSTRATE INHIBITORS OF KINASES

[02] This application claims priority to provisional U.S. Application Ser. No. 60/190,799, filed March 21, 2000, the disclosure of which is expressly incorporated herein.

[03] This invention was made under terms of grant CSK/NIH/R29CA74305 from the U.S. National Institutes of Health. The U.S. government therefore retains certain rights in the invention.

[04] FIELD OF THE INVENTION

[05] The invention relates to the development of highly specific inhibitors for kinase enzymes which are involved in processes including inflammation, cancer, cardiovascular disease, endocrine disorders, immunomodulators, Alzheimer's disease, diabetes, and restenosis.

[06] BACKGROUND OF THE INVENTION

[07] Protein kinases play a critical role in cell signalling pathways by catalyzing transfer of the  $\gamma$ -phosphoryl group from ATP to the hydroxyl groups of protein side chains<sup>1</sup>. Approximately 2% of eukaryotic genes encode protein kinases making this one of the largest protein superfamilies. Because of their importance in contributing to a variety of pathophysiologic states including cancer, inflammatory conditions, autoimmune disorders, and cardiac diseases, there have been intense efforts to develop specific protein kinase inhibitors as biological tools and as therapeutic agents<sup>2</sup>. Considerable success has been achieved developing potent and selective nucleotide-based analog inhibitors that interact with individual protein kinases at their nucleotide binding sites, and several compounds are in early phases of human clinical

trials<sup>2</sup>. In general, the protein substrate binding site has not been exploited for inhibitor design<sup>3</sup>. Moreover, mechanism-based approaches to generating protein kinase inhibitors have been unsuccessful<sup>4-8</sup>. This situation stands in contrast to many other important enzyme classes, such as the proteases, where consideration of enzyme mechanism and structure has led to potent inhibitors, some of which are clinically useful drugs<sup>9</sup>.

[08] Protein kinases follow ternary complex kinetic mechanisms in which direct transfer of the phosphoryl group from ATP to protein substrate occurs<sup>10</sup>. For such mechanisms, designing covalently linked bisubstrate analogs can be a powerful approach toward potent enzyme inhibitors<sup>9</sup>. However, previous attempts to employ this strategy with protein kinases have met with mixed results<sup>4, 8, 11</sup>. A sophisticated effort reported by Gibson and colleagues linked ATP directly to the serine oxygen of a protein kinase A (PKA) peptide substrate (kemptide) to generate an inhibitor (1, Fig. 1a)<sup>8</sup>. Compound 1 was a weak inhibitor with an IC<sub>50</sub> of 226 mM (compared to K<sub>m</sub> (ATP) of 10 mM and K<sub>m</sub> (kemptide) of 15 mM) which was competitive versus ATP but non-competitive versus peptide substrate. While not providing all the desired features of a bisubstrate analog, these results suggest that improvements in geometry and electronic character around the atoms equivalent to the entering nucleophile and reacting phosphate would benefit inhibitor design. There is a need in the art for kinase inhibitors which are stronger than those currently available.

[09] BRIEF SUMMARY OF THE INVENTION

[10] In a first embodiment of the invention a bisubstrate inhibitor of insulin receptor kinase is provided. The inhibitor comprises a nucleotide or nucleotide analog moiety and a peptide moiety. The moieties are linked by a tether that comprises a proton donor. The tether is  $\geq 4.9$  Å measured from a gamma phosphorus of the nucleotide or nucleotide analog moiety to the proton donor.

- [11] In a second embodiment of the invention a method of inhibiting insulin receptor kinase (IRK) is provided. IRK is contacted with a bisubstrate inhibitor which comprises a nucleotide or nucleotide analog moiety and a peptide moiety. The two moieties are linked by a tether that comprises a proton donor. The tether is  $\geq 4.9$  Å measured from a gamma phosphorus of the nucleotide or nucleotide analog to the proton donor, whereby the IRK is competitively inhibited.
- [12] In another embodiment of the invention a bisubstrate inhibitor of protein kinase A (PKA) is provided. The inhibitor comprises a nucleotide or nucleotide analog moiety and a peptide moiety. The moieties are linked by a tether that comprises a proton donor. The tether is  $\geq 4.9$  Å measured from a gamma phosphorus of the nucleotide or nucleotide analog to the proton donor.
- [13] In still another embodiment of the invention a method is provided for inhibiting protein kinase A (PKA). A bisubstrate inhibitor is contacted with PKA. The inhibitor comprises a nucleotide or nucleotide analog moiety and a peptide moiety. The moieties are linked by a tether that comprises a proton donor and which is  $\geq 4.9$  Å measured from a gamma phosphorus of the nucleotide or nucleotide analog to the proton donor. The inhibitor competitively inhibits the PKA enzyme.
- [14] In yet another embodiment of the invention a bisubstrate inhibitor of a protein kinase is provided. The inhibitor comprises a nucleotide or nucleotide analog moiety and a peptide moiety. The two moieties are linked by a tether that comprises a proton donor, wherein the tether is  $\geq 4.9$  Å measured from a gamma phosphorus of the nucleotide or nucleotide analog to the proton donor. The inhibitor can be contacted with the kinase to inhibit the enzyme activity.
- [15] The invention thus provides the art with inhibitory compounds and methods of inhibiting protein kinases, including the serine kinases, the threonine kinases, and the tyrosine kinases. In addition, the invention provides a general method of designing bisubstrate inhibitors for other kinases based on the dissociative transition state.

[16] BRIEF DESCRIPTION OF THE DRAWINGS

[17] Fig. 1. Synthetic compounds and mechanistic schemes. a, Designed protein kinase bisubstrate analog inhibitors. Compound 1 was synthesized and studied by Gibson and colleagues<sup>8</sup> as a potential PKA inhibitor. Compound 2 was designed based on a dissociative transition state for phosphoryl transfer. Distance between the anilino nitrogen and the gamma- phosphorus was calculated using Chem3D assuming an extended conformation of the acetyl linker. The peptide sequence is derived from IRS72727. Compound 3 was prepared to evaluate the relative contribution of the peptide residues toward inhibition. b, Scheme illustrating associative vs dissociative transition states for phosphoryl transfer. ROH is the nucleophile (tyrosine phenol in this work) attacking the  $\gamma$ -phosphoryl group of ATP, and ADP is the leaving group. Associative transition state (path A) in this work is defined as more than 50% bond formation between the nucleophilic oxygen and the phosphorus, which occurs with at least 50% leaving group residual bond formation present. Dissociative transition state (path B) in this work is defined as less than 50% bond formation between the nucleophile and the phosphorus, which occurs before the leaving group-phosphorus bond is at least 50% broken. c, Synthetic scheme toward the preparation of bisubstrate analog 2. R1 = AcNH-Lys-Lys-Lys-Leu-Pro-Ala-Thr-Gly-Asp- ; R2 = -Met-Asn-Met-Ser-Pro-Val-Gly-Asp-CO<sub>2</sub>H; R3 = R1 with side chain protected residues; R4 = R2 with side chain protected residues and Asp linked to Wang resin.

[18] Fig. 2. Kinetic analysis of the inhibition of IRK by Bisubstrate Analog 2. Assays were carried out using activated recombinant IRK as described previously.<sup>6</sup> a, E/V vs. 1/ATP in the presence of varying [2]. Conditions: fixed IRS727 concentration (120 mM), 20 mM MgCl<sub>2</sub>, 0.5 mM DTT, 6 nM IRK, 0.05% bovine serum albumin, Tris-Acetate pH 7, 10 min reaction time. b, E/V vs. 1/IRS727 in the presence of varying [2]. Conditions same as for a except fixed ATP (80 mM), 8 nM IRK and 5 min

reaction time. Duplicate measurements agreed within  $\pm 15\%$ . Data for a and b were globally fit to the equation for linear competitive inhibition:

[19]  $v = V_m(S)/[K_m(1 + I/K_i) + S]$ ;  $v$  = initial velocity,  $V_m$  = maximal velocity,  $S$  = substrate concentration,  $K_m$  = Michaelis constant. For a, apparent  $K_i$  (2) =  $550 \pm 80$  nM, for b, apparent  $K_i$  (2) =  $750 \pm 90$  nM. Inclusion of a  $K_i$ -intercept term (for a mixed competitive inhibition calculation) for either analysis did not reduce standard errors in the global fit and led to very high standard errors for the  $K_i$ -intercept terms, thereby adding confidence to our selection of linear competitive inhibition for a and b. c, Product/Enzyme versus Time. This experiment monitors the product formation after a rapid dilution of the enzyme/inhibition complex to indirectly measure the  $k_{off}$  of 2 from IRK. Conditions: Incubation of 1 mM IRK +/- 5 mM 2 for 10 min in reaction buffer (20 mM  $MgCl_2$ , 0.5 mM DTT, 0.05% BSA, 50 mM Tris-Acetate, pH 7) then dilute 1:50 into reaction buffer containing 1 mM ATP and 250 mM peptide6 IRS939 and measure conversion by HPLC at times shown. To determine  $k_{off}$ , data were fit to the equation<sup>17</sup>:

[20]  $P = v_s \cdot (t - [1 - e^{-k_{off} t}]) / k_{off}$ ;  $P$  = Product concentration,  $v_s$  = steady-state velocity,  $t$  = time and  $k_{off}$  is the first-order rate constant for dissociation of 2 from the enzyme.  $k_{off} = 0.013 \pm 0.001 \text{ s}^{-1}$ .

[21] Fig. 3 Crystal structure of the binary complex between cIRK and the bisubstrate inhibitor. a, Overall view of the binary complex in which cIRK is shown in surface representation and the bisubstrate inhibitor in stick representation. The ATPyS moiety of the inhibitor is colored green, the peptide moiety is colored red, and the linker connecting the nucleotide and peptide is colored yellow. The cIRK surface is semi-transparent; the N-terminal lobe of cIRK partially masks the nucleotide. b, Stereo view of the Fo-Fc electron density (2.7 Å resolution, 3s contour) for the bisubstrate

inhibitor computed after simulated annealing (1000K), omitting from the atomic model either ATPγS + linker (blue map) or the peptide moiety (green map). Coloring of the bisubstrate inhibitor is the same as in a. Selected peptide residues are labeled; Y'(P0) refers to the modified tyrosine at the P0 position of the peptide. The purple sphere represents the Mg<sup>2+</sup> ion and the red sphere represents the Mg<sup>2+</sup>-coordinating water molecule. c, Stereo view of the interactions between the inhibitor and key catalytic residues. Superimposed are the cIRK-bisubstrate inhibitor ternary complex are semi-transparent. Mg<sup>2+</sup> ions and water molecules are represented as purple and red spheres, respectively. Hydrogen bonds and bonds to the Mg<sup>2+</sup> ion are represented as dashed and solid black lines, respectively. Only the modified tyrosine from the peptide moiety (binary) complex and the cIRK-MgAMPPNP-peptide (ternary) complex<sup>15</sup>. Oxygen atoms are colored red, nitrogen atoms blue, sulfur atoms green, and phosphorus atoms yellow. Bonds/carbon atoms are colored orange for the binary complex and green for the ternary complex. Bonds and atoms of the t of the inhibitor is shown. 'BSI' indicates the bisubstrate inhibitor in the binary complex, 'Y(P0)' the substrate tyrosine in the ternary complex, and 'PNP' the ATP analog AMPPNP in the ternary complex. Selected secondary structural elements (aC and b3) are shown. Figure prepared with GRASP28, BOBSCRIPT29, and MOLSCRIPT30.

- [22] Fig. 4 shows the synthesis and structure of the kemptide-ATPγS conjugate as an inhibitor of protein kinase A.
- [23] Fig. 5 shows a kinetic inhibition assay for protein kinase A.
- [24] Fig. 6 shows substitutable groups for the triphosphates of ATP in a bisubstrate kinase inhibitor.
- [25] DETAILED DESCRIPTION OF THE INVENTION
- [26] It is a discovery of the present invention that design and manipulation of the dimensions of bisubstrate inhibitors of protein kinases can dramatically improve their inhibitory properties. In particular, the inventors have designed the distance between

the two substrate-like moieties to mimic the dimensions of a dissociative transition state, *i.e.*, a dimension of greater than 4.9 Å measured from a gamma phosphorus of the nucleotide or nucleotide analog moiety to the proton donor in the peptide moiety.

[27] Bisubstrate inhibitors typically contain one moiety which is a nucleotide or nucleotide analog moiety, which mimics the natural substrate ATP. Suitable moieties include ATP, ATP $\gamma$ -S, GTP, CTP, TTP, UTP, GTP $\gamma$ -S, CTP $\gamma$ -S, TTP $\gamma$ -S, UTP $\gamma$ -S, genistein, staurosporine, K252, quercetin. Analogs of nucleotides to which cells are more permeable are preferred. Analogs may, for example, have uncharged alkyl groups in place of one or more of the phosphate groups. Such alkyl groups may be C<sub>1</sub> to C<sub>6</sub> alkyl groups, including methyl, ethyl, butyl, pentyl, hexyl, and the branched chain isomers thereof. Preferably the alkyl groups will be C<sub>1</sub> to C<sub>3</sub>. These groups may be optionally substituted by one or more halo, hydroxy, alkoxy, amino, or lower alkylamino groups. Examples of possible replacements for the phosphate groups of a nucleotide are shown in Fig. 6.

[28] Bisubstrate inhibitors typically contain a second moiety which is a peptide having residues similar to that of the natural protein substrates of the particular protein kinase. Such peptides can be determined for each additional protein kinase by methods known in the art, including but not limited to library-based techniques<sup>22, 23</sup>. One peptide useful for the insulin receptor kinase is known in the art and called irktide (Lys, Lys, Lys, Leu, Pro, Ala, Thr, Gly, Asp, Tyr, Met, Asn, Met, Ser, Pro, Val, Gly, Asp (SEQ ID NO:1)). A peptide useful for protein kinase A is known in the art and called kemptide (Leu, Arg, Arg, Ala, Ser, Leu, Gly (SEQ ID NO:2)). Peptides can be modified as described in more detail below. The peptide moieties of the bisubstrate inhibitors need not contain all of the amino acid residues identified above. Fewer may be required than the total. Thus as few as 4, 5, 6, or 7 of the amino acid residues may be sufficient to provide the requisite specificity. In addition, the residues may be modified to improve their access to cells. For example, membrane translocating sequences are known in the art and can be appended to the

peptides of the bisubstrate inhibitors. One such sequence is AAVALLPAVLLALLAP (SEQ ID NO:3) See *J. Bio. Chem.* 270: 14255, 1995 and *Nature Biotech.* 16: 370, 1998. Such sequences can be advantageously placed at the N-terminal or C-terminal. A Human Immunodeficiency Virus TAT sequence can also be used to improve access to cells by the bisubstrate inhibitors. See Schwarze *et al.*, *Science* 285:1569, 1999. One means of stabilizing the peptide sequence is to substitute carbon-carbon bonds in place of amide bonds. Other suitable replacements include that of NH with O (depsipeptide), use of urethane moieties to replace one or more amino acid residues, and the use of peptoids to replace amino acid residues. See *J. Med. Chem.* 37:2678 (1994) and *Angewandte Chemie Int'l Ed.* 34:907 (1995). Such peptides, peptoids, peptidomimetics are within the contemplation of the invention and are referred to herein as peptide moieties.

[29] In order to make particular inhibitors with suitable tethers, the tyrosine residue of irkide is modified so that the phenolic oxygen is replaced with a nitrogen. Similarly, for the inhibitor of PKA, the serine residue is modified by substituting a nitrogen for the hydroxyl oxygen. Similarly, for threonine protein kinases, the hydroxyl oxygen can be replaced with a nitrogen. The tethers can comprise carbon, hydrogen, or oxygen atoms.

[30] The bisubstrate inhibitor of insulin receptor kinase (IRK) can be used to inhibit the kinase *in vitro* and *in vivo*. *In vitro* it can be used to study mechanism. The inhibitor can be bound to the kinase and crystallized. The structure of the bound complex can be determined as is known in the art, *e.g.* by X-ray crystallography and/or NMR. The structure can be used to design still better inhibitors. *In vivo* it can be administered to achieve therapeutic ends. Thus it can be used to combat inflammation, cancer, cardiovascular disease, endocrine disorders, immune disorders, Alzheimer's disease, diabetes, and restenosis. The bisubstrate inhibitors can be administered by any means known in the art, including but not limited to intravenous, intramuscular, subcutaneous, intraperitoneal, and orally.

- [31] A bisubstrate inhibitor of protein kinase A (PKA) is also provided. It too, contains a nucleotide or nucleotide analog moiety and a peptide moiety. The moieties are linked by a tether that comprises a proton donor. The tether is  $\geq 4.9$  Å measured from a gamma phosphorus of the nucleotide or nucleotide analog to the proton donor. The PKA inhibitor differs from the IRK inhibitor in the peptide moiety. Not only is the nature of the peptide moiety different, presumably reflecting the kinases' different physiological substrates, but the linkage to the tether differs. In the case of the PKA inhibitor the hydroxyl oxygen of the serine residue is replaced with a nitrogen, forming a diaminopropionic acid residue.
- [32] Like the IRK inhibitor, the PKA inhibitor can be used to inhibit its enzyme target either *in vitro* or *in vivo*. Thus the compound can be contacted with the enzyme in a cell free system, suitable for kinetic studies, in cells in culture, and in whole animals, where therapeutic effects can be obtained. Other bisubstrate kinase inhibitors can be similarly used.
- [33] The present invention establishes a new approach to protein kinase inhibition based in part on mechanistic and structural considerations of a predicted dissociative transition state for these enzymes. This method is generalizable to other protein kinases based on the distinctive peptide substrate sequence selectivities of the individual enzymes. This permits design of inhibitors as biological and structural tools based on the peptide specificity of a protein kinase. Peptide specificity can be established by one of several library-based techniques<sup>22, 23</sup>. Whereas lead compounds may demonstrate suboptimal pharmacokinetic properties due to substituents which are peptides and nucleotides, such properties can be improved using phosphate surrogates and peptidomimetics as discussed above. Since different protein kinases may have overlapping peptide substrate selectivities, greater specificity for inhibition of individual kinases may also be achieved by synthetic refinements of the nucleotide and peptide moieties. By adding a new dimension of molecular recognition to the already high potency of nucleotide analog-based protein kinase inhibitors, these

mechanism-based inhibitors constitute an entirely new class of therapeutically useful agents.

[34] While the invention has been described with respect to specific examples including presently preferred modes of carrying out the invention, those skilled in the art will appreciate that there are numerous variations and permutations of the above described systems and techniques that fall within the spirit and scope of the invention as set forth in the appended claims.

[35] Examples

[36] Example 1—design of inhibitor of IRK

[37] Compound 1 has a Ser-O-to-P bond distance (1.7 Å) more compatible with a fully associative reaction mechanism for phosphoryl transfer by a protein serine kinase (Fig. 1b). In such a transition state a bond is largely formed between the attacking oxygen and the reactive  $\gamma$ -phosphorus atom, while the bond to the departing ADP would not yet have been significantly broken (Fig. 1b). In contrast, recent studies of two protein tyrosine kinases in which the nucleophilicity of the attacking tyrosyl's hydroxyl was varied have provided strong evidence for a dissociative or metaphosphate-like transition state<sup>6, 12</sup>. A dissociative transition state for phosphoryl transfer catalyzed by a protein kinase, analogous to an SN1 reaction in organic chemistry, is one in which the importance of nucleophilicity of the attacking hydroxyl is diminished and departure of the leaving group (ADP) is well advanced (Fig. 1b). Dissociative transition states are well-established for non-enzymatic phosphate monoester phosphoryl transfer reactions but have been considered more controversial for the corresponding enzyme-catalyzed reactions<sup>13, 14</sup>. A prediction for such a fully dissociative transition state is that the 'reaction coordinate distance' between the entering nucleophilic oxygen and the attacked phosphorus should be  $\geq 4.9$  Å. This is based on the assumptions that the  $\gamma$ -phosphoryl group moves toward the entering

oxygen and that this nucleophile and the ADP are fixed, probably as they appear in the ground-state ternary complex that precedes the transition state<sup>14</sup>.

[38] For a transition state with greater associative character, the reaction coordinate distance could be  $\geq 3.3$  Å, indicating compression<sup>14</sup>. High resolution X-ray and NMR structures of various protein kinase complexes with nucleotide and peptide substrate analogs have yielded conflicting values for such distances<sup>14-16</sup>, however these studies by necessity have employed unreactive substrate analogs which could affect the outcomes.

[39] In reconsidering the design of a bisubstrate analog based on the above parameters of (largely) dissociative reaction mechanisms for protein kinases, we hypothesized that a peptide-ATP bisubstrate analog 2 in which the distance between the tyrosine nucleophilic atom and the  $\gamma$ -phosphorus was set to approximately 5 Å (5.66 Å in extended form; Fig. 1a) by a short linker might show more potent inhibition toward a protein tyrosine kinase than 1 showed toward PKA. A second design feature was based on the fact that proton removal from the tyrosine's hydroxyl occurs late in the dissociative reaction mechanism,<sup>6, 12</sup> and that the phenolic hydroxyl serves as a hydrogen bond donor to the conserved catalytic aspartate (Asp 1132 of the insulin receptor). To exploit this interaction, the tyrosine oxygen was replaced with a nitrogen atom which could serve as a hydrogen bond donor while simultaneously being incorporated into a tether. Our choice of target enzyme for the inhibitor was the insulin receptor protein tyrosine kinase (IRK) because: 1) efficient peptide substrates (including IRS727) for this enzyme have been well characterized kinetically<sup>6</sup>; 2) solution phase studies have provided direct evidence for a dissociative transition state for this enzyme<sup>6</sup>; 3) a high resolution crystal structure of this enzyme in a ternary complex with peptide substrate and an ATP analog has been determined<sup>15</sup>; and 4) no potent inhibitors have been reported for this important signalling enzyme or for the highly related insulin-like growth factor receptor protein tyrosine kinase.

[40] Example 2--Synthesis and kinetic analysis of a bisubstrate inhibitor

[41] Synthesis of compound 2 was carried out as shown in Fig. 1c. The protected peptide was assembled using solid-phase peptide synthesis using Fmoc chemistry, in which the single tyrosine of IRS727 was replaced with commercially available nitrophenylalanine. The nitro group was reduced with  $\text{SnCl}_2$  and the aniline function was bromoacetylated via standard coupling conditions. The peptide was cleaved from the resin and deblocked with trifluoroacetic acid, water, and thioanisole and purified by reversed phase HPLC. The bromoacetylated peptide was reacted with ATPyS in aqueous solution at pH 7, which resulted in chemoselective displacement of the bromide by the phosphorothioate. The peptide-ATP conjugate 2 was purified by reversed phase HPLC and characterized by electrospray mass spectrometry and  $^1\text{H}$  NMR. While it was stable in aqueous solution at neutral pH and room temperature for >12 h, it was unstable in acidic solution (pH 2), decomposing with a half life of ~2 hours. It could be stored in frozen solution at  $-80^\circ\text{C}$  for several weeks without detectable decomposition.

[42] Methods

[43] Synthesis of compounds 2 and 3

[44] The nitrophenylalanine peptide starting material (Fig. 1c) was assembled on Wang resin using automated solid phase peptide synthesis via the Fmoc strategy (0.3 mmol scale). While still in the solid phase, the nitro group was reduced with  $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$  (6 mmol) in dimethylformamide for 24 h at room temperature with gentle stirring. It was washed with dimethylformamide and  $\text{CH}_2\text{Cl}_2$  and dried. The resin was then treated with bromoacetic acid (2.5 mmol), diisopropylcarbodiimide (2.5 mmol) in dimethylformamide for 5 h at room temperature with gentle mixing. The resin was washed and dried as above prior to treatment with cleavage and deblocking conditions (5 mL trifluoroacetic acid, 1.5 mL  $\text{CH}_2\text{Cl}_2$ , 0.25 mL  $\text{H}_2\text{O}$ , 0.1 mL thioanisole) for 30

min at room temperature. The particulate was removed by filtration through scintered glass and the filtrate was concentrated and treated with cold ether to precipitate the bromoacetylated peptide. The crude bromoacetylated peptide was washed once more with cold ether, dried under vacuum, and purified by preparative reversed phase HPLC (gradient with  $\text{H}_2\text{O}:\text{CH}_3\text{CN}$ : 0.05%  $\text{CF}_3\text{CO}_2\text{H}$ , UV monitored at 214 nm) to yield 71 mg of pure material, and electrospray mass spectrometry was used to confirm its structural identity. The purified bromoacetylated peptide (17 mg) was dissolved in 4:1  $\text{MeOH}:\text{H}_2\text{O}$  (3.6 mL) and treated with ATP  $\gamma\text{S}$  (adenosine 5'-O-3-thiotriphosphate, Boehringer, 0.02 mmol) for 24 h at room temperature. The conjugate 2 was subsequently purified by reversed phase HPLC (gradient with  $\text{H}_2\text{O}:\text{CH}_3\text{CN}$ , neutral pH, UV monitored at 214 or 260 nm) and lyophilized to yield 12 mg. Electrospray mass (negative ion) and  $^1\text{H}$  NMR spectra confirmed the correctness of the assigned structure. The concentration of 2 in aqueous solution was determined by amino acid analysis (Harvard Univ. Microchemistry Facility). The compound was stored at pH 7 in aqueous solution at  $-80^\circ\text{C}$  and periodically monitored for decomposition by HPLC.

[45]        Synthesis of 3 was carried out by reacting bromoacetanilide and ATP- $\gamma\text{S}$  analogous to the production of 2. The product 3 was purified by reversed phase HPLC and the pure product characterized by  $^1\text{H}$  NMR, electrospray mass spectrometry and quantified by UV.

[46]    Example 3-- Kinetics of inhibition

[47]        Kinase assays with compound 2 revealed it to be a potent inhibitor of IRK (Fig. 2). Using a steady-state kinetic analysis, compound 2 was a linear competitive inhibitor versus both nucleotide (Fig. 2a) and peptide (Fig. 2b) substrates with a  $K_i$  of 370 nM (extrapolated to zero substrates), which is 190-760 fold lower than the  $K_m$ 's of the substrates ( $K_{m \text{ app}}(\text{ATP}) = 71 \mu\text{M}$ ;  $K_{m \text{ app}}(\text{IRS727}) = 280 \mu\text{M}$ ). In an alternative

analysis of 2, the  $IC_{50} \sim 10 \mu M$  at a concentration of 1 mM ATP and 0.3 mM IRS727. By using a rapid dilution analysis, the  $k_{off}$  was measured to be  $0.013 s^{-1}$  (Fig. 2c), which is also consistent with its tight-binding behavior. The calculated second order rate constant  $k_{on}$  for 2 binding to IRK is  $3.5 \times 10^4 M^{-1}s^{-1}$  which is substantially slower than a predicted diffusional encounter rate ( $10^8$ - $10^9 M^{-1}s^{-1}$ ) and suggests that a "slow" conformational change may be responsible for reaching the tightly bound complex<sup>17</sup>. Compound 2 represents the most potent inhibitor yet reported for IRK. The potency of 2 compares favorably to bisubstrate analog inhibitors designed for other (non-protein kinase) enzymes<sup>9</sup>. The most potent bisubstrate analog inhibitors can show binding free energies equal to the sum of the binding energies of the two substrates. The binding energy of compound 2 (8.9 kcal/mol) is approximately equal to the sum of its two parts (4.1 kcal/mol for IRS727 peptide binding and 5.1 kcal/mol for ATP $\gamma$ S binding,) confirming that each substrate-like part of compound 2 contributes to the binding affinity.

[48] To further probe the basis of the potency of 2, the derivatized ATP analog 3 lacking the polypeptide portion of compound 2 was prepared and tested as an IRK inhibitor. It was a linear competitive inhibitor of IRK versus ATP with a  $K_i$  of 114  $\mu M$ . This is only 2-fold tighter binding than ATP- $\gamma$ S alone ( $K_i$  of 210  $\mu M$ ) and approximately 300-fold weaker as an inhibitor than 2, indicating that the peptide moiety is an essential contributor to the inhibitory potency of 2 and that the anilino-tethering group present in 3 accomplishes little by itself.

[49] An additional inhibitor was formed like compound 2 but containing only two phosphate groups on the nucleotide moiety. It was less than 100-fold as inhibitory as compound 2. This confirms the criticality of the tether distance of greater than 4.9 Å.

[50] The specificity of inhibition was also tested by assaying 2 as an inhibitor of the protein tyrosine kinase Csk18. The peptide binding selectivity for Csk is quite different from IRK, and the IRS727 peptide moiety would be predicted to bind poorly to this enzyme<sup>19</sup>. As anticipated 2 was only a modest inhibitor of Csk with an

approximate  $K_i = 40 \mu\text{M}$  ( $K_m$  (ATP) of  $195 \mu\text{M}$ ). Thus the bisubstrate analog approach should allow for kinase selectivity based in part on peptide sequence.

[51] Kinetic analysis of IRK inhibition by compound 2

[52] Assays were carried out using activated recombinant IRK as described previously<sup>6</sup>. For E/V vs. 1/ATP plot the conditions were: 120 mM IRS727 concentration, 20 mM  $\text{MgCl}_2$ , 0.5 mM DTT, 6 nM IRK, 0.05% bovine serum albumin, 50 mM Tris-Acetate pH 7, 10 min reaction time. For E/V vs. 1/IRS727 in the conditions were the same except fixed ATP (80 mM) was employed, 8 nM IRK and 5 min reaction time. Duplicate measurements agreed within  $\pm 15\%$ . Data for these plots were globally fit to the equation for linear competitive inhibition:

[53]  $v = V_m(S)/[K_m(1 + I/K_i) + S]$ ;  $v$  = initial velocity,  $V_m$  = maximal velocity,  $S$  = substrate concentration,  $K_m$  = Michaelis constant. Inclusion of a  $K_i$ -intercept term (for a mixed competitive inhibition calculation) for either analysis did not reduce standard errors in the global fit and led to very high standard errors for the  $K_i$ -intercept terms, thereby adding confidence to our selection of the linear competitive inhibition model for these plots.

[54] For the  $k_{\text{off}}$  measurement of compound 2 from IRK, the conditions: Incubation of 1 mM IRK +/- 5 mM 2 for 10 min in reaction buffer (20 mM  $\text{MgCl}_2$ , 0.5 mM DTT, 0.05% BSA, 50 mM Tris-Acetate, pH 7) then dilute 1:50 into reaction buffer containing 1 mM ATP and 250 mM peptide<sup>6</sup> IRS939 and measure conversion by HPLC at times shown. To determine  $k_{\text{off}}$ , data were fit to the equation<sup>17</sup>:

[55]  $P = v_s(t - [1 - e^{-k_{\text{off}} t}])/k_{\text{off}}$ ,  $P$  = Product concentration,  $v_s$  = steady-state velocity,  $t$  = time and  $k_{\text{off}}$  is the first-order rate constant for dissociation of 2 from the enzyme.  $k_{\text{off}} = 0.013 \pm 0.001 \text{ s}^{-1}$ .

[56] Example 4--Crystal Structure of compound 2 bound to the insulin receptor kinase

[57] To understand the structural details of IRK inhibition by 2, we determined the crystal structure of 2 bound to the core tyrosine domain of the insulin receptor (cIRK) at 2.7 Å resolution (Table 1 and Fig. 3). cIRK was autophosphorylated in vitro to yield the tris-phosphorylated, activated form of cIRK in which Tyr 1158, Tyr 1162, and Tyr 1163 in the activation loop are phosphorylated. The bisubstrate inhibitor was co-crystallized with cIRK, producing trigonal crystals with the same unit cell dimensions as crystals of the ternary complex (cIRK/IRS727/MgAMPPNP)<sup>15</sup>. The inhibitor-cIRK structure is very similar to the structure of the ternary complex, with an overall root-mean-square deviation of only 0.22 Å for 303 Ca atoms of cIRK.

Table 1. X-ray data collection and refinement statistics

Data collection	
Resolution (Å)	30.0 – 2.7
Observations	42217
Unique reflections	9633
Completeness (%)	96.5 (91.9)1
R <sub>sym</sub> 2 (%)	11.4 (33.9)1
Refinement	
Number of atoms	
Protein	2370
Inhibitor	125
Water	23
Mg2+	2
Resolution (Å)	30.0 – 2.7
Reflections	9342
R <sub>cryst</sub> 3 / R <sub>free</sub> (%)	21.4 / 27.0
R. m. s. deviations	
Bond lengths (Å)	0.007
Bond angles (°)	1.5
B-factors4 (Å <sup>2</sup> )	1.3
Average B-factors (Å <sup>2</sup> )	
All atoms	20.6
Protein	20.1
Inhibitor (ATPγ S + linker)	15.4
Inhibitor (peptide)	34.2

1Overall (30.0 – 2.7 Å) value given first, followed by value (in parentheses) in the highest resolution shell (2.8 – 2.7 Å).

$$2R_{\text{sym}} = 100 \times \sum || - \langle I \rangle| / \sum I.$$

$$3R_{\text{cryst}} = 100 \times \sum ||F_o| - |F_c|| / \sum |F_o|, \text{ where } F_o \text{ and } F_c \text{ are the observed and calculated structure factors, respectively } (F_o > 0\sigma). R_{\text{free}}$$

determined from 5% of the data.

4For bonded protein atoms.

[58] Several remarkable features were observed in the active site of cIRK. First, two mechanism-based design components were validated: 1) the distance between the  $\gamma$ -phosphorus and the anilino nitrogen atom (corresponding to the phenolic oxygen of tyrosine) was 5.0 Å, the expected reaction coordinate length for a dissociative mechanism as discussed above; 2) a 3.2 Å hydrogen bond between the anilino nitrogen and the key catalytic aspartate (Asp 1132) was evident. Serendipitously, the carbonyl oxygen of the linker is coordinated to a  $Mg^{2+}$  ion ( $O-Mg = 2.2$  Å), replacing a water molecule at that position in the ternary complex (Fig. 3c) and preserving the octahedral coordination of this  $Mg^{2+}$  ion. A second  $Mg^{2+}$  ion appears to have a lower occupancy in the binary complex than was observed in the ternary complex. In the binary complex, the side chain of invariant Lys 1030 is hydrogen-bonded to invariant Glu 1047 as well as to the  $\alpha$ -phosphate group. This is in contrast to the ternary complex in which a hydrogen bond from Lys 1030 to the  $\alpha$ -phosphate group was observed, but the Lys 1030 – Glu 1047 distance was 4.4 Å. A salt bridge between the invariant lysine and glutamate may be required for efficient phosphoryl transfer 20.

[59] The peptide moiety of the bisubstrate inhibitor binds to cIRK in a similar manner to that observed in the ternary complex<sup>15</sup>: an anti-parallel  $\beta$ -strand interaction is present between residues P+1 - P+3 of the peptide and Gly 1169 - Leu 1171 of the activation loop, and the P+1 and P+3 methionines are positioned in shallow hydrophobic pockets on the surface of the C-terminal kinase lobe. Several IRS727 residues that had been disordered in the ternary complex, P-3 to P-5 and P+4 to P+7, are visible in the complex with the bisubstrate inhibitor (same unit cell), suggesting a more stable interaction (Fig. 3b). The peptide portion of the bisubstrate inhibitor outside of the core recognition region (P-1 to P+3) follows a unique path (Fig. 3a). Interestingly, the residues N-terminal to the modified tyrosine do not lie along the extended peptide binding groove defined largely by residues in  $\alpha$ -helix D, as observed for PKI bound to PKA21; the P-5 proline of the bisubstrate inhibitor is adjacent to

Gly 1005 of the nucleotide-binding loop in the N-terminal lobe. This may be due to charge repulsion between the three N-terminal lysines of the peptide moiety and Arg 1089 and Arg 1092 of cIRK, which are exposed on  $\alpha$ -helix D. In addition, residues at the C-terminus of the peptide moiety (P+4, etc.) lie in a shallow groove bounded by the activation loop and  $\alpha$ -helices EF and G. This latter interaction was unanticipated and could possibly be associated with slow release of the peptide.

[60] Crystal structure of cIRK with compound 2

[61] Tris-phosphorylated cIRK (residues 978-1283) was prepared as described<sup>15</sup>. Crystals were grown at 4 °C by vapor diffusion in hanging drops containing 1.0  $\mu$ L of protein solution (280 mM cIRK (10 mg/mL), 400  $\mu$ M of the bisubstrate inhibitor, and 1.2 mM MgCl<sub>2</sub>) and 1.0  $\mu$ L of reservoir buffer (18% polyethylene glycol 8000, 100 mM Tris-HCl, pH 7.5). Crystals belong to space group P3221 with unit cell dimensions  $a = b = 66.3$  Å,  $c = 138.1$  Å. Crystals were transferred into a cryosolvent consisting of 30% polyethylene glycol 8000, 100 mM Tris-HCl, pH 7.5, and 15% ethylene glycol. A data set was collected from a flash-cooled crystal on a Rigaku RU-200 rotating anode equipped with a Rigaku R-Axis IIC image plate detector. Data were processed using DENZO and SCALEPACK24. Rigid-body, simulated annealing, positional and B-factor refinement were performed with CNS25 and model building with O26. Bulk solvent and anisotropic B-factor corrections were applied.

[62] Example 5--Synthesis of Kemptide-ATPyS conjugate as inhibitor of PKA

[63] An n-Alloc protecting group was added to the side chain amine of the commercially available diaminopropionic acid (DAP) residue by reacting DAP (500mg: 1.5 mmol) with allyl chloroformate (163  $\mu$ L: 1.5 mmol) in dimethylformamide (DMF) at room temperature for 24 hours. The protected residue was purified using silica gel size exclusion column chromatography (gradient elution MeOH: CH<sub>2</sub>Cl<sub>2</sub>). The eluting fractions were monitored using thin layer

chromatography, mass spectrometry and NMR. The fractions containing DAP(n-alloc) were combined, dried under vacuum and used to synthesize the DAP(n-alloc) kemptide peptide. The DAP(n-alloc) kemptide peptide (Figure 4) was prepared on a solid phase Wang resin (0.1 mmol scale) using Fmoc chemistry. The DAP(n-alloc) kemptide peptide was treated while on the solid phase with 70%  $\text{CH}_2\text{Cl}_2$ , 15% N-methyl morpholine, 15% acetic acid solution (5 mL) into which 450 mg tetrakis(triphenylphosphine) palladium (0) was added. This deprotection reaction was done under argon at room temperature for two hours with gentle shaking. The reaction solution was removed using a Poly Prep® chromatography filter column (BioRad) and the resin was washed with  $\text{CH}_2\text{Cl}_2$  (50 mL) before rinsing with a palladium chelating solution consisting of 20 mL DMF, 225 mg diethyldithiocarbamic acid:3H<sub>2</sub>O and 250 uL triethylamine (TEA). The resin was washed with 5%(v/v) TEA in DMF (50 mL) then methanol (50 mL) and dried. Bromoacetic acid (342 mg) was dissolved in a solution of DMF (5 mL) and diisopropylcarbodiimide (0.4 mL), added to the dried resin and allowed to react with the peptide for 5 hours at room temperature with gentle shaking. The resin was filtered and washed as described above, dried and then treated with a cleavage/deprotection solution (5 mL trifluoroacetic acid, 1.5 mL  $\text{CH}_2\text{Cl}_2$ , 250 (L ddH<sub>2</sub>O, 100 (L thioanisole) for 1 hr at room temperature. The released peptide was filtered from the resin, vacuum concentrated and then precipitated using cold ether (25 mL). The precipitate was dried under vacuum, dissolved in 7 mL of water and purified using reverse-phase preparative HPLC (gradient elution: H<sub>2</sub>O:CH<sub>3</sub>CN:0.05% trifluoroacetic acid (v/v), UV analysis at 214 nm) to give 7.9 mg of bromoacetylated peptide. The bromoacetylated product was dissolved in H<sub>2</sub>O (2 mL) and reacted with ATPγS (20 nmol) with stirring for 24 hours at room temperature. The kemptide-ATPγS conjugate was purified from the reaction mixture using reverse phase preparative HPLC (gradient elution: H<sub>2</sub>O, CH<sub>3</sub>CN) and dried under vacuum to produce a final yield of 7 mg kemptide-ATPγS conjugate. The composition of the conjugate was confirmed using electrospray mass spectrometry and NMR data

supported the proposed inhibitor structure. Concentration was determined using UV absorption at 260 nm.

[64] Example 6--Inhibition of PKA using Kemptide-ATPyS conjugate

[65] Preliminary assays using the kemptide-ATPyS conjugate as a specific inhibitor of protein kinase A (PKA) have been performed and show the conjugate to be inhibitory to PKA. Reagents from Calbiochem's Protein Kinase A kit were used to perform the inhibition assays and recombinant mouse PKA (catalytic subunit) was also purchased from Calbiochem (enzyme concentration was established by Bradford analysis). A 0.76 mM stock solution of kemptide-ATPyS conjugate was prepared and used to make serial dilutions into an aqueous  $\text{MgCl}_2$  solution (53 mM), producing a range of inhibitor concentrations from 144  $\mu\text{M}$  to 1.4  $\mu\text{M}$  with  $\text{Mg}^{2+}$  concentration of 47.7 mM. These were further diluted into water to produce a range of inhibitor solutions between 51  $\mu\text{M}$  and 507 nM. An 11.25  $\mu\text{L}$  aliquot from each of these solutions was pre-incubated with 7.5  $\mu\text{L}$  of a 1.75 nM PKA enzyme solution (750  $\mu\text{g}/\mu\text{L}$  bovine serum albumin) for 10 minutes at 30°C after which 12.5  $\mu\text{L}$  of pre-incubation mix was added to 12.5  $\mu\text{L}$  of reaction mix (30  $\mu\text{M}$  cold ATP, 50  $\mu\text{M}$  biotinylated kemptide substrate, 0.04  $\mu\text{Ci}/\mu\text{L}$   $\gamma\text{P-32}$  ATP, 80 mM Tris-HCl, 10 mM  $\text{MgCl}_2$ , pH 7.5) to initiate the enzymatic reaction. Reactions were quenched after 2 minutes with 10  $\mu\text{L}$  8.0 M guanidine HCl (8.0 M solution as reported by Calbiochem kit, however guanidine limit of solubility = 6 M), treated with avidin solution, then run through a centrifugation column to which the avidin-bound phosphokemptide would adhere. The columns were placed in scintillation vials and radioactivity was measured using a scintillation counter. Dixon plot analysis of the resultant inhibition data is shown in Fig. 5. The calculated  $K_i$  value versus ATP for this conjugate (assuming a reversible competitive inhibition model) is shown to be 9.56  $\mu\text{M}$ . If the  $K_i$  calculation is adjusted to account for zero substrate the  $K_i$  value decreases to 4.6  $\mu\text{M}$ .

[66] Bisubstrate analog inhibitors such as the conjugate above have generated considerable interest because of their potential to be highly selective inhibitors for their specific enzyme targets<sup>31</sup>. These compounds, designed to bind enzymes that form a ternary complex in the transition state, gain specificity by linking moieties derived from the target enzyme's natural substrates. One of the challenges inherent in bisubstrate analog inhibitor design is the requirement that the molecule effectively mimic what the enzyme would normally see in its transition state active site. This potential limitation is greatly reduced by having structural information about the target enzyme's active site as well as an understanding of the chemical reaction mechanism used by the enzyme. Structural and mechanistic data supporting a dissociative mechanism of phosphoryl transfer for the insulin receptor kinase was used to design a potent bisubstrate analog inhibitor against this enzyme ( $K_i = 370$  nM, extrapolated to zero substrate)<sup>32</sup>. The kemptide-ATP $\gamma$ S conjugate described above was designed based on the structural homology of PKA's active site to the active site of the insulin receptor kinase as well as mechanistic data implicating a dissociative chemical mechanism for PKA. The bisubstrate analog inhibitor approach has been previously attempted for PKA. A conjugate featuring an ATP moiety directly linked to the kemptide serine was shown to be a weak inhibitor of PKA ( $K_i = 226$   $\mu$ M versus ATP)<sup>33</sup>. The increased inhibition generated by our kemptide-ATP $\gamma$ S conjugate ( $K_i = 9.6$   $\mu$ M versus ATP) may be a result of improved electronic and steric design, thus creating a molecule that more accurately reflects the true reaction intermediate. Continued optimization of linker distances, electronic interactions and peptide composition hold the potential to generate a highly specific and even more potent inhibitor for PKA.

## References

- 1) Hunter, T., Cell 100, 113-127 (2000).
- 2) Showalter, H. D. & Kraker, A. J. Pharmacol. Ther. 76, 55-71 (1997).
- 3) Lawrence, D. S. & Niu, J. Pharmacol. Ther. 77, 81-114 (1998).
- 4) G. Rosse, G. et al. Helvetica Chimica Acta 80, 653-670 (1997).
- 5) Yuan, C. J., Jakes, S., Elliott, S. & Graves, D. J. Biol. Chem. 265, 16205-16209 (1990).
- 6) Ablooglu, A. J. et al. J. Biol. Chem. 275, 30394-30398 (2000).
- 7) Cushman, M. et al. Int. J. Pept. Protein Res. 36, 538-543 (1990).
- 8) Medzihradszky, D., Chen., S. L., Kenyon, G. L. & Gibson, B. W. J. Am. Chem. Soc. 116, 9413-9419 (1994).
- 9) Silverman, R. B., 'The Organic Chemistry of Drug Design and Drug Action' (Academic, NY, 1992).
- 10) Ho, M., Bramson, H. N., Hansen, D. E., Knowles, J. R. & Kaiser, E. T.J. Am. Chem. Soc. 110, 2680-2681 (1988).
- 11) Uri, A., Raidaru, G., Jarv, J. & Pia, E. Bioorg. Med. Chem. Lett. 9, 1447-1452 (1999).
- 12) Kim, K. & Cole, P. A. J. Am. Chem. Soc. 120, 6851-6858 (1998).

- 13) Admiraal, S. J. & Herschlag, D. J. *Am. Chem. Soc.* 122, 2145-2148 (2000).
- 14) Mildvan, A. S. *Proteins: Structure, Function, and Genetics* 29, 401-416 (1997).
- 15) Hubbard, S. R. *EMBO J.* 16, 5572-5581 (1997).
- 16) Brown, N. R., Noble, M. E. M., Endicott, J. A. & Johnson, L. N. *Nature Cell Biol.* 1, 438-443 (1999).
- 17) Morrison, J. F. & Walsh, C. T. *Adv. Enzymol.* 61, 201-301 (1988).
- 18) Grace, M. R., Walsh, C. T. & Cole, P. A. *Biochemistry* 36, 1874-1881 (1997).
- 19) Sondhi, D., Xu, W., Songyang, Z., Eck, M. J. & Cole, P. A. *Biochemistry* 37, 165-172 (1998).
- 20) Taylor, S. S. & Radzio-Andzelm, E. *Structure* 2, 345-355 (1994).
- 21) Knighton, D. R. et al. *Science* 253 414-420 (1991).
- 22) Songyang, Z. et al., *Nature* 373, 536-539 (1995).
- 23) Till, J. H., Annan, R. S., Carr, S. A. & Miller, W. T. *J. Biol. Chem.* 269, 7423-7428 (1994).
- 24) Otwinowski, Z. & Minor, W. *Methods Enzymol.* 276, 307-326 (1997).
- 25) Brünger, A. et al., *Acta Crystallogr. D* 54, 905-921 (1998).
- 26) Jones, T. A. *Methods Enzymol.* 115, 157-171 (1985).

- 27) Shoelson, S. E., Chatterjee, S., Chandhuri, M. & White, M. F. Proc. Natl. Acad. Sci. USA 89, 2027-2031 (1992).
- 28) Nicholls, A., Sharp, K. A. & Honig, B. Proteins 11, 281-296 (1991).
- 29) Esnouf, R. M. J. Mol. Graph. 15, 132-134 (1997).
- 30) Kraulis, P. J. J. Appl. Crystallogr. 24, 946-950 (1991).
- 31) Silverman, R.B. *The organic chemistry of drug design and drug action* (Academic Press, New York; 1992)
- 32) Parang, K., Till, J.H., Ablooglu, A.J., Kohanski, R.A., Hubbard, S.R., Cole, P.A. *Nature Structural Biology* 8, 37-41 (2001).
- 33) Medzihradszky, D., Chen, S.L., Kenyon, G.L., Gibson, B.W. *J. Am. Chem. Soc.* 116 9413-9419 (1994).

**We Claim:**

1. A bisubstrate inhibitor of insulin receptor kinase, comprising:  
a nucleotide or nucleotide analog moiety;  
and a peptide moiety;  
wherein said moieties are linked by a tether that comprises a proton donor, wherein the tether is  $\geq 4.9$  Å measured from a gamma phosphorus of the nucleotide or nucleotide analog moiety to the proton donor.
2. The bisubstrate inhibitor of claim 1 wherein the nucleotide or nucleotide analog moiety is ATP.
3. The bisubstrate inhibitor of claim 1 wherein the nucleotide or nucleotide analog moiety is  $\gamma$ -S-ATP.
4. The bisubstrate inhibitor of claim 1 wherein the peptide comprises a tyrosine residue in which its phenolic oxygen is replaced with a nitrogen atom.
5. The bisubstrate inhibitor of claim 1 wherein the peptide moiety has at least 4 contiguous amino acid residues selected from the sequence Lys, Lys, Lys, Leu, Pro, Ala, Thr, Gly, Asp, Tyr, Met, Asn, Met, Ser, Pro, Val, Gly, Asp (SEQ ID NO:1).
6. The bisubstrate inhibitor of claim 1 wherein the peptide moiety has at least 5 contiguous amino acid residues selected from the sequence Lys, Lys, Lys, Leu, Pro, Ala, Thr, Gly, Asp, Tyr, Met, Asn, Met, Ser, Pro, Val, Gly, Asp (SEQ ID NO:1).
7. The bisubstrate inhibitor of claim 1 wherein the peptide moiety comprises the sequence Lys, Lys, Lys, Leu, Pro, Ala, Thr, Gly, Asp, Tyr, Met, Asn, Met, Ser, Pro, Val, Gly, Asp (SEQ ID NO:1).
8. The bisubstrate inhibitor of claim 1 wherein the nucleotide or nucleotide analog moiety is a nucleotide in which one or more phosphate groups are replaced by uncharged alkyl groups.

9. The bisubstrate inhibitor of claim 1 wherein the nucleotide or nucleotide analog moiety is a nucleotide in which one or more phosphate groups are replaced by uncharged C<sub>1</sub> to C<sub>3</sub> alkyl groups.
10. The bisubstrate inhibitor of claim 1 wherein the peptide moiety comprises a membrane translocating sequence (MTS).
11. The bisubstrate inhibitor of claim 10 wherein the MTS is at the N-terminus of the peptide moiety.
12. The bisubstrate inhibitor of claim 10 wherein the MTS is at the C-terminus of the peptide moiety.
13. The bisubstrate inhibitor of claim 1 wherein the peptide moiety comprises an HIV TAT sequence.
14. The bisubstrate inhibitor of claim 1 wherein the peptide moiety comprises carbon-carbon bonds in place of amide bonds.
15. The bisubstrate inhibitor for the insulin receptor tyrosine kinase of claim 1 which is Compound 2.
16. A method of inhibiting insulin receptor kinase (IRK) comprising:  
contacting IRK with a bisubstrate inhibitor comprising a nucleotide or nucleotide analog moiety and a peptide moiety, wherein said moieties are linked by a tether that comprises a proton donor, wherein the tether is  $\geq 4.9$  Å measured from a gamma phosphorus of the nucleotide or nucleotide analog to the proton donor, whereby the IRK is competitively inhibited.
17. The method of claim 16 wherein the nucleotide or nucleotide analog moiety is ATP.
18. The method of claim 16 wherein the nucleotide or nucleotide analog moiety is  $\gamma$ S-ATP.
19. The method of claim 16 wherein the peptide comprises a tyrosine residue in which its phenolic oxygen is replaced with a nitrogen atom.
20. The method of claim 16 wherein the peptide moiety has at least 4 contiguous amino acid residues selected from the sequence Lys, Lys, Lys, Leu,

Pro, Ala, Thr, Gly, Asp, Tyr, Met, Asn, Met, Ser, Pro, Val, Gly, Asp  
(SEQ ID NO:1).

21. The method of claim 16 wherein the peptide moiety has at least 5 contiguous amino acid residues selected from the sequence Lys, Lys, Lys, Leu, Pro, Ala, Thr, Gly, Asp, Tyr, Met, Asn, Met, Ser, Pro, Val, Gly, Asp (SEQ ID NO:1).
22. The method of claim 16 wherein the peptide moiety comprises the sequence Lys, Lys, Lys, Leu, Pro, Ala, Thr, Gly, Asp, Tyr, Met, Asn, Met, Ser, Pro, Val, Gly, Asp (SEQ ID NO:1).
23. The method of claim 16 wherein the nucleotide or nucleotide analog moiety is a nucleotide in which one or more phosphate groups are replaced by uncharged alkyl groups.
24. The method of claim 16 wherein the nucleotide or nucleotide analog moiety is a nucleotide in which one or more phosphate groups are replaced by uncharged C1 to C4 alkyl groups.
25. The method of claim 16 wherein the peptide moiety comprises a membrane translocating sequence (MTS).
26. The method of claim 25 wherein the MTS is at the N-terminus of the peptide moiety.
27. The method of claim 25 wherein the MTS is at the C-terminus of the peptide moiety.
28. The method of claim 16 wherein the peptide moiety comprises an HIV TAT sequence.
29. The method of claim 16 wherein the peptide moiety comprises carbon-carbon bonds in place of amide bonds.
30. A bisubstrate inhibitor of protein kinase A (PKA) comprising:  
a nucleotide or nucleotide analog moiety; and  
a peptide moiety;

wherein said moieties are linked by a tether that comprises a proton donor, wherein the tether is  $\geq 4.9$  Å measured from a gamma phosphorus of the nucleotide or nucleotide analog to the proton donor.

31. The bisubstrate inhibitor of claim 30 wherein the nucleotide or nucleotide analog moiety is ATP.
32. The bisubstrate inhibitor of claim 30 wherein the nucleotide or nucleotide analog moiety is  $\gamma$ S-ATP.
33. The bisubstrate inhibitor of claim 30 wherein the peptide comprises a diaminopropionic acid residue.
34. The bisubstrate inhibitor of claim 30 wherein the peptide moiety has at least 4 contiguous amino acid residues selected from the sequence Leu, Arg, Arg, Ala, diaminopropionic acid, Leu, Gly (SEQ ID NO:2).
35. The bisubstrate inhibitor of claim 30 wherein the peptide moiety has at least 5 contiguous amino acid residues selected from the sequence Leu, Arg, Arg, Ala, diaminopropionic acid, Leu, Gly (SEQ ID NO:2).
36. The bisubstrate inhibitor of claim 30 wherein the peptide moiety comprises the sequence Leu, Arg, Arg, Ala, diaminopropionic acid, Leu, Gly (SEQ ID NO:2).
37. The bisubstrate inhibitor of claim 30 wherein the nucleotide or nucleotide analog moiety is a nucleotide in which one or more phosphate groups are replaced by uncharged alkyl groups.
38. The bisubstrate inhibitor of claim 30 wherein the nucleotide or nucleotide analog moiety is a nucleotide in which one or more phosphate groups are replaced by uncharged C<sub>1</sub> to C<sub>3</sub> alkyl groups.
39. The bisubstrate inhibitor of claim 30 wherein the peptide moiety comprises a membrane translocating sequence (MTS).
40. The bisubstrate inhibitor of claim 39 wherein the MTS is at the N-terminus of the peptide moiety.
41. The bisubstrate inhibitor of claim 39 wherein the MTS is at the C-terminus of the peptide moiety.

42. The bisubstrate inhibitor of claim 30 wherein the peptide moiety comprises an HIV TAT sequence.
43. The bisubstrate inhibitor of claim 30 wherein the peptide moiety comprises carbon-carbon bonds in place of amide bonds.
44. A method of inhibiting protein kinase A (PKA) comprising:  
contacting PKA with a bisubstrate inhibitor comprising a nucleotide or nucleotide analog moiety and a peptide moiety, wherein said moieties are linked by a tether that comprises a proton donor, wherein the tether is  $\geq 4.9$  Å measured from a gamma phosphorus of the nucleotide or nucleotide analog to the proton donor, whereby the PKA is competitively inhibited.
45. The method of claim 44 wherein the nucleotide or nucleotide analog moiety is ATP.
46. The method of claim 44 wherein the nucleotide or nucleotide analog moiety is  $\gamma$ S-ATP.
47. The method of claim 44 wherein the peptide comprises a diaminopropionic acid residue.
48. The method of claim 44 wherein the peptide moiety has at least 4 contiguous amino acid residues selected from the sequence Leu, Arg, Arg, Ala, diaminopropionic acid, Leu, Gly (SEQ ID NO:2).
49. The method of claim 44 wherein the peptide moiety has at least 5 contiguous amino acid residues selected from the sequence Leu, Arg, Arg, Ala, diaminopropionic acid, Leu, Gly (SEQ ID NO:2).
50. The method of claim 44 wherein the peptide moiety comprises the sequence Leu, Arg, Arg, Ala, diaminopropionic acid, Leu, Gly (SEQ ID NO:2).
51. The method of claim 44 wherein the nucleotide or nucleotide analog moiety is a nucleotide in which one or more phosphate groups are replaced by uncharged alkyl groups.

52. The method of claim 44 wherein the nucleotide or nucleotide analog moiety is a nucleotide in which one or more phosphate groups are replaced by uncharged C1 to C4 alkyl groups.
53. The method of claim 44 wherein the peptide moiety comprises a membrane translocating sequence (MTS).
54. The method of claim 53 wherein the MTS is at the N-terminus of the peptide moiety.
55. The method of claim 53 wherein the MTS is at the C-terminus of the peptide moiety.
56. The method of claim 44 wherein the peptide moiety comprises an HIV TAT sequence.
57. The method of claim 44 wherein the peptide moiety comprises carbon-carbon bonds in place of amide bonds.
58. The bisubstrate inhibitor of claim 1 which is bound to insulin receptor kinase.
59. The bisubstrate inhibitor of claim 32 which is bound to protein kinase A.
60. A bisubstrate inhibitor of a protein kinase comprising:
  - a nucleotide or nucleotide analog moiety; and
  - a peptide moiety;wherein said moieties are linked by a tether that comprises a proton donor, wherein the tether is  $\geq 4.9$  Å measured from a gamma phosphorus of the nucleotide or nucleotide analog to the proton donor.
61. The bisubstrate inhibitor of claim 60 wherein the protein kinase is a serine protein kinase.
62. The bisubstrate inhibitor of claim 60 wherein the protein kinase is a threonine protein kinase.
63. The bisubstrate inhibitor of claim 60 wherein the protein kinase is a tyrosine protein kinase.
64. The bisubstrate inhibitor of claim 61 wherein a nitrogen atom replaces a hydroxyl oxygen on the serine.

65. The bisubstrate inhibitor of claim 62 wherein a nitrogen atom replaces a hydroxyl oxygen on the threonine.
66. The bisubstrate inhibitor of claim 63 wherein a nitrogen atom replaces a hydroxyl oxygen on the tyrosine.
67. The bisubstrate inhibitor of claim 60 which is bound to the protein kinase.
68. The bisubstrate inhibitor of claim 30 which has the structure of Compound 4.

FIG. 1








FIG. 2




3/6  
**FIG. 3**

*a**b**c*


4/6

FIG. 4




Compound 4


$R_1$  = AcNH-Leu-Arg-Arg-Ala-  
 $R_2$  = -Leu-Gly-COOH  
 $R_3$  =  $R_1$  with Arg protecting groups  
 $R_4$  =  $R_2$  with Gly linked to Wang resin

**FIG. 5**


Inhibition assay for protein kinase A.  
Final concentrations for reaction components : ATP = 15 uM,  
kemptide = 25 uM, Mg<sup>2+</sup> = 10mM, Tris-HCl = 40 mM,  
bovine serum albumin (from enzyme mix) 150 ug/mL.  
All reactions were carried out at pH 7.5 and with a  
final enzyme concentration of 0.35 nM  
for 2 minutes at 30 degrees Celsius.

**FIG. 6**R'=CH<sub>2</sub>CO-peptide or peptidomimetic


R=adenosine or nucleoside analog



n=0-6




n=0-6




n=0-6

X=O, NH, S, CH<sub>2</sub>  
 Y=O, NH, S, CH<sub>2</sub>

X=O, NH, S, CH<sub>2</sub>

n=0-6



n=0-6

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
27 September 2001 (27.09.2001)

PCT

(10) International Publication Number  
WO 01/070770 A3

(51) International Patent Classification<sup>7</sup>: C07K 7/08,  
A61K 47/48, 38/10

(21) International Application Number: PCT/US01/08886

(22) International Filing Date: 21 March 2001 (21.03.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 60/190,799 21 March 2000 (21.03.2000) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:  
US 60/190,799 (CON)  
Filed on 21 March 2000 (21.03.2000)

(71) Applicant (for all designated States except US): THE  
JOHNS HOPKINS UNIVERSITY [US/US]; 111 Market  
Place, Suite 906, Baltimore, MD 21202 (US).

(72) Inventors: and

(75) Inventors/Applicants (for US only): COURTNEY, Aliya

[US/US]; JHMI, 725 N. Wolfe Street, 316 Hunterian Bldg.,  
Baltimore, MD 21205 (US). COLE, Philip, A. [US/US]; 5  
Wendover Road, Baltimore, MD 21218 (US). PARANG,  
Keykavous [CA/US]; Apt. 7019, 3333 North Charles  
Street, Baltimore, MD 21218 (US). ABLOOGU, Ararat  
[TR/US]; 50 East 98th Street, Apt. 2F, New York, NY  
10029 (US). KOHANSKI, Ron [US/US]; 8-24 Fairhaven  
Place, Fair Lawn, NJ 07410 (US).


(74) Agents: KAGAN, Sarah, A. et al.; Banner & Witcoff,  
Ltd., 1001 G Street, N.W., Eleventh Floor, Washington, DC  
20001-4597 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,  
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,  
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,  
TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE).

[Continued on next page]

(54) Title: BISUBSTRATE INHIBITORS OF KINASES



(57) Abstract: Protein kinase inhibitors have applications as anti-cancer therapeutic agents and biological tools in cell signalling. Potent and selective bisubstrate inhibitors for the insulin receptor tyrosine kinase are based on a phosphoryl transfer mechanism involving a dissociative transition state. One such inhibitor is synthesized by linking ATP<sub>γ</sub>S to a peptide substrate analog via a two-carbon spacer. The compound is a high-affinity competitive inhibitor against both nucleotide and peptide substrate and shows a slow off-rate. A crystal structure of this inhibitor bound to the tyrosine kinase domain of the insulin receptor confirms the key design features inspired by a dissociative transition state, and reveal that the linker takes part in the octahedral coordination of an active site Mg<sup>2+</sup> ion.

WO 01/070770 A3



IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(88) Date of publication of the international search report:  
4 July 2002

**Published:**

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

# INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 01/08886

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 C07K7/08 A61K47/48 A61K38/10

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, MEDLINE, BIOSIS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>RICOUART A ET AL: "DESIGN OF POTENT PROTEIN KINASE INHIBITORS USING THE BISUBSTRATE APPROACH"</p> <p>JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 34, no. 1, 1991, pages 73-78, XP002918324</p> <p>ISSN: 0022-2623</p> <p>See especially page 73, column 1; page 74, column 1</p> <p style="text-align: center;">--- -/-</p>	1-68

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

### \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*A\* document member of the same patent family

Date of the actual completion of the international search

5 February 2002

Date of mailing of the international search report

27/02/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Groenendijk, M

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 01/08886

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	HUBBARD S R: "Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog" EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 16, no. 18, 1997, pages 5572-5581, XP002088043 ISSN: 0261-4189 cited in the application The whole document; see especially page 5578, column 2 ---	1-68
P,X	MILLER: "Double trouble" NATURE STRUCTURAL BIOLOGY, vol. 8, no. 1, January 2001 (2001-01), pages 16-18, XP001053333 the whole document ---	1-68
P,X	PARANG E.A.: "Mechanism-based design of a protein kinase inhibitor" NATURE STRUCTURAL BIOLOGY, vol. 8, no. 1, January 2001 (2001-01), pages 37-41, XP001053332 the whole document ---	1-68
Y	MEDZIHRADESKY DENES ET AL: "Solid-phase synthesis of adenosine phosphopeptides as potential bisubstrate inhibitors of protein kinases" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC, US, vol. 116, no. 21, 1994, pages 9413-9419, XP002150234 ISSN: 0002-7863 cited in the application the whole document ---	30-57, 59-68
A	ROSSE, GERARD ET AL: "Synthesis of modified tripeptides and tetrapeptides as potential bisubstrate inhibitors of the epidermal growth factor receptor protein tyrosine kinase" HELV. CHIM. ACTA (1997), 80(3), 653-670 , XP002188862 See especially page 654 ---	1-68
	--- -/-- ---	

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/08886

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>KIM E.A.: "Kinetic analysis of a protein tyrosine kinase reaction transition state in the forward and reverse directions" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 120, no. 28, 22 July 1998 (1998-07-22), pages 6851-6858, XP002188863  DC US  the whole document -----</p>	1-68

## FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

Continuation of Box I.2

Claims Nos.: 1-4,8-19,23-33,37-47,51-68

Present claims 1,16,30,44 and 60 relate to an extremely large number of possible compounds (and their use). Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Moreover the majority of said compounds is only defined by a minimum length of the tether, lacking any other structural properties. Hence said claims also lack clarity within the meaning of Article 6 PCT to such an extent as to render a meaningful search of the whole of the claimed scope of said claims impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the compounds defined in the claims 5-7 and 34-36 and their use and also for the general concept underlying the claims 1,16,30,44, and 60.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**